Could a new eye drop beat an old favorite for glaucoma?
NCT ID NCT07617532
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a new eye drop, DNN.31.19.026, against a standard treatment (Cosopt) for people with high eye pressure or open-angle glaucoma. About 336 adults will use the drops twice daily for 56 days. The main goal is to see if the new drop lowers eye pressure better and is just as safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DNN.31.19.026 eye drops
- What this could lead to
- If successful, this could offer a new, safe option for lowering eye pressure in people with glaucoma or ocular hypertension.
- What could go wrong
- This is a Phase 3 trial, but it's not yet recruiting. The new eye drops may not lower pressure better than the existing drug Cosopt, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tiny eye implant replace glaucoma drops?
- Which laser best tames glaucoma pressure?
- Could a single eye implant replace years of glaucoma drops?
- Which eye implant best tames glaucoma? a head-to-head trial aims to find out.
- Could a simple home workout protect eyesight in glaucoma?
- One drop before the laser: could this simple step save your sight?